[{"id":"3436b807-cfe6-466a-bed6-261455f869e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04433494","created_at":"2021-01-18T21:20:56.931Z","updated_at":"2024-07-02T16:35:59.476Z","phase":"Phase 1","brief_title":"A Study of TY-302 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04433494","lead_sponsor":"TYK Medicines, Inc","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Soltamox (tamoxifen citrate) • TY-302"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/07/2020","start_date":" 12/07/2020","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-12-07"}]